Alterity Therapeutics Clears FDA Phase 3 Trial Design
The FDA has endorsed the pivotal trial design for Alterity Therapeutics' experimental drug ATH434 to treat multiple system atrophy.
Updated on Oct. 30, 2026 in Biotech
Live Poll
Do you generally trust pharmaceutical companies to successfully develop new medical treatments?
Alterity Therapeutics successfully aligned with the FDA on the design of its pivotal Phase 3 clinical trial for ATH434. The study aims to evaluate the efficacy of the drug in treating patients diagnosed with multiple system atrophy.
Why it matters
Securing FDA approval for a trial design is a critical step in the path toward a potential new drug application. The company must provide data from a pivotal trial bolstered by confirmatory evidence to advance the therapy toward commercial use.
The study will enroll 200 patients randomized to receive either a 50-milligram dose of ATH434 or a placebo administered twice daily. The primary endpoint for this 12-month trial is the 11-item Unified Multiple System Atrophy Rating Scale Part I.
The players
Alterity Therapeutics
This is a biotech company focused on developing therapies for neurodegenerative diseases including multiple system atrophy.
FDA
This federal agency is responsible for protecting public health by regulating the safety and efficacy of human drugs.
The details
Alterity Therapeutics has manufactured the first registration batch of the drug to support the upcoming study. The company holds a U.S. patent for the crystalline mesylate salt form of ATH434, which provides intellectual property protection through 2045.
Timeline
August 2026: Alterity received a U.S. patent for ATH434.
September 2026: Financial quarter ended for cash balance reporting.
October 2026: Additional Phase 2 study analyses were presented.
12 months: Duration planned for the upcoming Phase 3 trial.
The Tech Race
The use of the Unified Multiple System Atrophy Rating Scale for drug trials follows established protocols for measuring neurodegenerative progression. This study utilizes this scale as its primary endpoint to quantify clinical efficacy against established neurological standards.
The successful trial design alignment moves the company closer to providing a potential treatment option for patients with this neurodegenerative condition. While this news does not affect current drug availability, it marks progress in the research pipeline for those waiting for new therapies.
The takeaway
The FDA's endorsement of the trial design provides a clear regulatory roadmap for Alterity Therapeutics to proceed with its Phase 3 study. This milestone is essential for any biotech firm seeking to move an experimental treatment from clinical trials to market access.
Further reading
For more information on current developments in the sector, visit our Biotech section.
Source note: This article includes information reported by Small Caps.
Live Poll
Do you generally trust pharmaceutical companies to successfully develop new medical treatments?
